These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31122565)

  • 1. A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treatment.
    Liu J; Li X; Peng J
    J Thorac Oncol; 2019 Jun; 14(6):e126-e128. PubMed ID: 31122565
    [No Abstract]   [Full Text] [Related]  

  • 2. Early-onset interstitial pneumonitis in a patient with advanced non-small cell lung cancer treated with crizotinib and osimertinib.
    Cheng Y; Yu Q; Xiong Y; Guo C; Nie L
    Thorac Cancer; 2021 Mar; 12(5):690-692. PubMed ID: 33438350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
    Giroux-Leprieur E; Dumenil C; Chinet T
    J Thorac Oncol; 2018 Nov; 13(11):e232-e234. PubMed ID: 30368417
    [No Abstract]   [Full Text] [Related]  

  • 4. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.
    Ham JS; Kim S; Kim HK; Byeon S; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Han J; Park W; Ahn MJ
    J Thorac Oncol; 2016 Jan; 11(1):e1-4. PubMed ID: 26762749
    [No Abstract]   [Full Text] [Related]  

  • 5. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.
    Tang K; Jiang N; Kuang Y; He Q; Li S; Luo J; Jiang W; Chen Y; Sun Y; Chen L; Chen Y; Zhu J; Cui Y; Wan H; Ke Z
    Thorac Cancer; 2019 Feb; 10(2):359-364. PubMed ID: 30521113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    Yoshida H; Ooi M; Kim YH
    J Thorac Oncol; 2018 Nov; 13(11):e219-e220. PubMed ID: 30368410
    [No Abstract]   [Full Text] [Related]  

  • 7. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
    Yang JC; Shepherd FA; Kim DW; Lee GW; Lee JS; Chang GC; Lee SS; Wei YF; Lee YG; Laus G; Collins B; Pisetzky F; Horn L
    J Thorac Oncol; 2019 May; 14(5):933-939. PubMed ID: 30763730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.
    York ER; Varella-Garcia M; Bang TJ; Aisner DL; Camidge DR
    J Thorac Oncol; 2017 Jul; 12(7):e85-e88. PubMed ID: 28274743
    [No Abstract]   [Full Text] [Related]  

  • 9. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.
    Ou SI; Agarwal N; Ali SM
    Lung Cancer; 2016 Aug; 98():59-61. PubMed ID: 27393507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Leighl NB; Karaseva N; Nakagawa K; Cho BC; Gray JE; Hovey T; Walding A; Rydén A; Novello S
    Eur J Cancer; 2020 Jan; 125():49-57. PubMed ID: 31838405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).
    Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
    Thorac Cancer; 2020 Sep; 11(9):2389-2397. PubMed ID: 32677256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
    Pinquie F; Cortot AB; Chevalier LM; Morel A; Sandrini J; Guguen C; Morvan B; Molinier O
    Clin Lung Cancer; 2022 Mar; 23(2):e131-e134. PubMed ID: 34548228
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of efficacy and prognosis of Osimertinib combined with docetaxel for non-small cell lung cancer.
    Huang Y; Shi Y; Yin X; Zhang Q
    J BUON; 2020; 25(2):805-810. PubMed ID: 32521871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
    Zhang L; Sun L; Mu XY; Ji YX
    Chin Med Sci J; 2019 Nov; 34(4):292-296. PubMed ID: 33906716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.
    Kang J; Chen HJ; Wang Z; Liu J; Li B; Zhang T; Yang Z; Wu YL; Yang JJ
    J Thorac Oncol; 2018 Apr; 13(4):e49-e53. PubMed ID: 29128427
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
    Wang Y; Li L; Han R; Jiao L; Zheng J; He Y
    Lung Cancer; 2018 Apr; 118():105-110. PubMed ID: 29571987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
    Deng L; Kiedrowski LA; Ravera E; Cheng H; Halmos B
    J Thorac Oncol; 2018 Sep; 13(9):e169-e172. PubMed ID: 30166014
    [No Abstract]   [Full Text] [Related]  

  • 19. Osimertinib Called "Home Run" for
    Cancer Discov; 2020 Jul; 10(7):896. PubMed ID: 32487567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved CNS Control With the Addition of Chemotherapy to Osimertinib: A Devil's Bargain?
    Yu Y; Miao E; Pike LRG
    J Clin Oncol; 2024 Jun; 42(17):2107-2108. PubMed ID: 38569123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.